

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

OC 02120

315557

Licensee

1. St. Joseph Mercy - Oakland

2. 44405 Woodward Avenue  
Pontiac, MI 48341-5023

In accordance with letters dated **July 6, 2006,**  
**July 25, 2006, and August 31, 2006,**

3. License number 21-11651-01 is amended in  
its entirety to read as follows:

4. Expiration date **November 30, 2010**

5. Docket No. 030-02104

Reference No.

6. Byproduct, source, and/or special  
nuclear material

7. Chemical and/or physical form

8. Maximum amount that licensee may  
possess at any one time under this  
license

A. Any byproduct material  
permitted by 10 CFR 35.100

A. Any

A. As needed

B. Any byproduct material  
permitted by 10 CFR 35.200

B. As needed

C. Any byproduct material  
permitted by 10 CFR 35.300

C. As needed (not to exceed  
curie of iodine-131)

D. Any byproduct material  
identified in 10 CFR 35.400

D. 3 curies

E. Iridium-192

E. Source (Amersham  
Model 2000)

E. 200 millicuries

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

B. Any imaging and localization study permitted by 10 CFR 35.200.

C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

E. To be used for interstitial treatment of cancer.

# **MATERIALS LICENSE SUPPLEMENTARY SHEET**

License Number  
21-11651-01

Docket or Reference Number  
030-02104

Amendment No. 52

## CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at 44405 Woodward Avenue, Pontiac, Michigan.
11. The Radiation Safety Officer is **Michael M. Joh, M.D.**
12. Licensed material is only authorized for use by, or under the supervision of:
  - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
  - B. The following individuals are authorized users for medical use as indicated:

### Authorized Users


### Material and Use

<b>Raymond P. Rahi, M.D.</b>	10 CFR 35.100, and 35.200
Jennifer Webb Holt, M.D.	10 CFR 35.400, Iridium-192 wire
<b>Adnan R. Habbal, M.D.</b>	10 CFR 35.100, 35.200, 35.300 and 35.500
Laird E. Olson, M.D.	Strontium-89 (as included in 10 CFR 35.300), 35.400, and
Nitin G. Vaishampayan, M.D.	Strontium-89 (as included in 10 CFR 35.300), 35.400, and
Kay T. Miller, M.D.	Strontium-89 (as included in 10 CFR 35.300), 35.400, and
Mark J. Fireman, M.D.	10 CFR 35.400 and Iridium-192 wire
Ahmed E. Ezz, M.D.	Strontium-89 (as included in 10 CFR 35.300), 35.400 and
	iridium-192 wire
<b>Michael M. Joh, M.D.</b>	10 CFR 35.100, 35.200 and 35.300
<b>Kyoung Soo Bae, M.D.</b>	10 CFR 35.100, 35.200 and 35.300
<b>Anthony P. Munaco, M.D.</b>	10 CFR 35.100, and 35.200
<b>Tushar Parikh, M.D.</b>	10 CFR 35.100, 35.200 and 35.300
<b>James E. Denier, M.D.</b>	10 CFR 35.100, 35.200 and 35.300
<b>Won Chae, M.D.</b>	10 CFR 35.100 and 35.200
<b>John Kalabat, M.D.</b>	10 CFR 35.100, 35.200 and 35.300

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
21-11651-01Docket or Reference Number  
030-02104

Amendment No. 52

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated November 2, 2000 (with attachments, excluding QMP); and
- B. Letters dated April 24, 1995 (with attachments, limited to iridium-192 wire procedures), May 15, 1995 (limited to iridium-192 wire procedures), November 2, 1995, February 12, 2001 (except Item 12. (QMP modifications)), March 8, 2001, November 29, 2001, June 11, 2002, August 28, 2002 (with attachments), **August 31, 2006**.
- C. Facsimiles dated July 18, 2005 (documentation for removal of Gd-153 disposal), October 18, 2005, and October 19, 2005.




FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date

SEP 05 2006

By

  
James R. Mullauer, M.H.S.  
Materials Licensing Branch  
Region III